Reduction in myocardial infarct size by basic fibroblast growth factor following coronary occlusion in a canine model

International Journal of Cardiology

Volumn 68, Issue SUPPL. 1, 1999, Pages

  Horrigan, Mark C G ^b   Malycky, Janis L ^b   Ellis, Stephen G ^b   Topol, Eric J ^b   Nicolini, Francesca A ^a,b  

^a Fondazione Cardiologica Myriam Z   (Italy)

^b Department of Cardiology   (United States)

Author keywords

Acute myocardial ischemia; Basic fibroblast growth factor; Infarct size

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR;

ACUTE HEART INFARCTION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY PERMEABILITY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; HEART INFARCTION SIZE; HEART MUSCLE NECROSIS; HEART MUSCLE REVASCULARIZATION; HEMODYNAMIC MONITORING; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL;

ANIMALS; DISEASE MODELS, ANIMAL; DOGS; FIBROBLAST GROWTH FACTOR 2; HEMODYNAMIC PROCESSES; MYOCARDIAL INFARCTION; NECROSIS; REGIONAL BLOOD FLOW; TREATMENT OUTCOME;

EID: 0033541530     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(98)00296-4     Document Type: Article

References (22)

1. Unger EF, Banai S, Shou M, Lazarous DF, Jaklitsch MT, Scheinowitz M, Correa R, Klingbeil C, Epstein SE. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 1994;266:H1588-95.
2. Unger EF, Shou M, Sheffield CD, Hodge E, Jaye M, Epstein SE. Extracardiac to coronary anastomoses support regional left ventricular function in dogs. Am J Physiol 1993;264:H1567-74.
3. Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, Kamijo T, Sugimoto T, Kaji K, Utsuyama M, Kurashima C, Ito H. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992;257:1401-3.
4. Horrigan MCC, MacIsaac AI, Nicolii FA, Vince G, Lee P, Ellis SG, Topol EJ. Reduction in myocardial infarct size by basic fibroblast growth factor following temporary coronary occlusion in a canine model. Circulation 1996;94:1927-33.
5. Winldes JA, Friesel R, Burgess WH, Howk R, Mehlman T, Weinstein R, Maciag T. Human vascular smooth muscle cells both express and respond to heparin-binding growth factor I (endothelial cell growth factor). Proc Natl Acad Sci USA 1987;84:7124-8.
6. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 1986;83:7297-301.
7. Pasyk S, Schaper W, Schaper J, Pasyk K, Miskiewicz G, Steinseifer B. DNA synthesis in coronary collaterals after coronary artery occlusion in conscious dog. Am J Physiol 1982;242:H1031-7.
8. Montesano R. Regulation of angiogenesis in vitro. Eur J Clin Invest 1992;22:504-15.
9. Schaper W, De Brabander M, Lewi P. DNA synthesis and mitoses in coronary collateral vessels of the dog. Circ Res 1971;28:671-9.
10. Bache RJ. Effect of exercise and pharmacologic interventions on coronary collateral blood flow. In: Schaper W, Schaper J, editors. Collateral Circulation, Heart, Brain, Kidney, Limbs. Boston: Kluwer Academic Publishers; 1993:173-94.
11. Cuevas P, Carceller F, Ortega S, Zazo M, Nieto I, Gimenez-Gallego G. Hypotensive activity of fibroblast growth factor. Science 1991;254:1208-10.
12. Lazarous DF, Scheinowitz M, Shou M, Hodge E, Rajanayagam S, Hunsberger S, Robinson WG, Stiber JA, Correa R, Epstein SE, Unger EF. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 1995;91:145-53.
13. Majors A, Ehrhart LA. Basic fibroblast growth factor in the extracellular matrix suppresses collagen synthesis and type III procollagen mRNA levels in arterial smooth muscle cell cultures. Arterioscier Thromb 1993;13:680-6.
14. Vivaldi MY, Kloner RA, Schoen FJ. Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats. Am J Pathol 1985;121:522-30.
15. Roberts AJ, Cipriano PR, Alonso DR, Jacobstein JG, Combes JR, Gay WA. Evaluation of methods for quantification of experimental myocardial infarction. Circulation 1978;57:35-41.
16. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, Corday E, Ganz W. Early phase of acute myocardial infarct size quantification: validation of the triphenyltetrazolium chloride technique. Am Heart J 1981;101:593-600.
17. Silver MJ, Sutton JM, Hook S, Lee P, Malycky IL, Phillips LM, Ellis SG, Topol EJ, Nicolini FA. Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation 1995;92:492-9.
18. Domenech RJ, Hoffman SE, Noble MM, Saunders KB, Henson RJ, Subyanto S. Total and regional coronary blood flow measured by radioactive microspheres in conscious and anesthetized dogs. Circ Res 1969;23:581-96.
19. Klagsburn M, Baird A. A dual receptor system is required for basic fibroblast growth factor activity. Cell 1991;67:229-31.
20. Tilly IL, Billig H, Kowalski KI, Hsueh AJ. Epidermal growth factor and basic fibroblast growth factor suppress the spontaneous onset of apoptosis in cultured rat ovarian granulosa cells and follicles by a tyrosine kinase-dependent mechanism. Mol Endocrinol 1992;6:1942-50.
21. Jérôme V, Léger J, Devin J, Baulieu EE, Catelli MG. Growth factors acting via tyrosine kinase receptors induce HSP9O α gene expression. Growth Factors 1991;4:317-27.
22. Baird A. Potential mechanisms regulating the extracellular activities of basic fibroblast growth factor (FGF-2). Mol Reprod Devel 1994;39:43-8.